On July 7, 2026, the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA™ (atacicept-vymj). The therapy is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. Vera Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases.
